Novartis AG (NVS) said Thursday that it is upgrading its mid-term sales growth guidance to 6% for 2023 to 2028, compared with 5% previously.
The company expects to grow sales by 5% from 2024 to 2029, rolling forward its mid-term guidance with 2024 as the base year.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments